FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT
Exhibit 10.19(ii)
FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT
THIS FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT (the “License Amendment”) is made and entered into as of February 18, 2015 by and between THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (“UT’’), a corporation vested with the government, management and control of the University of Toronto by the University of Toronto Act, 1971 and having offices at Banting Institute, 000 Xxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx, Xxxxxxx, Xxxxxx, X0X 0X0 and PROTAGENIC TIIERAPEUTICS, INC. a corporation incorporated under the laws of Delaware and having a principal place of business at 000 0xx Xxxxxx, Xxxxx 000, Xxx Xxxx, XX 00000, X.X.X. (“Licensee”).
BACKGROUND:
| A. | The Licensee and the University of Toronto Innovations Foundation (“UTIF”) entered into a technology license agreement effective July 21, 2005 (“License Agreement”). |
| B. | Effective May 1, 2006, UTIF ceased to operate its business and it transferred and assigned all of its business and assets to UT and the License Agreement continued under the same terms and conditions aside from UT replacing UTIF in said License Agreement. |
| C. | UT and Licensee entered into a sponsored research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16, 2007; March 17, 2008; March 18, 2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1, 2013 and may enter into additional sponsored research agreements (collectively the “Research Agreement”). |
| D. | UT and Licensee wish for improvements (as defined in the License Agreement and listed under Schedule A hereto), created by Xxxxx Xxxxxxx and/or other research participants under the Research Agreement while employed by UT, to be included in the License. |
| E. | UT and Licensee wish to amend the License Agreement in accordance with the conditions hereof. |
NOW THEREFORE, the Parties hereto agree to further amend and revise the License Agreement as follows:
All capitalized terms not defined herein shall have the same meaning ascribed to such terms as set out in the License Agreement.
| 1. | All references to the University of Toronto Innovations Foundation and “UTIF” are hereby deleted and replaced with The Governing Council of the University of Toronto and “UT” respectively. |
2. Section 1.1 -Definitions.
The definition of “Improvements” is hereby deleted in its entirety and replaced with the following:
“Improvements” means any and all improvements, variations, updates, modifications or enhancements to the Technology (including without limitation any related Intellectual Property Rights) which are developed under the terms of a research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16, 2007; March 17, 2008; March 18, 2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1,2013, and under the terms of any other sponsored research agreement designated in same as being added by reference to Schedule B of this Agreement and this Agreement shall be deemed to be amended accordingly to incorporate all such sponsored research agreements as a Research Agreement by reference between Licensee and The Governing Council of the University of Toronto.
The definitions of “Phase I End”, “Phase II End” and “Phase III End” are hereby deleted in their entirety and replaced with the following:
“Phase I End” means approval by the FDA or other applicable regulatory authority to commence Phase II Clinical Trials of each Licensed Product as such trials are described in 21 C.F.R. 312.2 l(b);
“Phase II End” means approval by the FDA or other applicable regulatory authority to Commence Phase III Clinical Trials of each Licensed Product as such trials are described in 21 C.F.R.3 12.21(c);
“Phase III End” means Regulatory Approval of each Licensed Product;
The definition for “University” is hereby deleted in its entirety and replaced with the following:
“University” means The Governing Council of the University of Toronto.
3. Section 2.1(a) -Grant of License for Technology
Section 2.1 (a) is hereby deleted in its entirety and replaced with the following;
(a) an exclusive license within the Territory and within the Field of Use to develop, make, have made, use, sell, offer for sale and import the Technology and Licensed Products under all Owners’ and/or Xxxxx Xxxxxxx’x and or UT rights, title and interest in the Technology and Licensed Products; and
4. Section 3.1 -Royalty
Section 3.1(f) is added as follow:
f) For clarity, Upfront Sub-License Fees shall exclude any and all research and development payments, reimbursements, loans and equity investments in the Company and payments made in respect of a collaboration agreement or acquisition agreement, whether such payments are for research milestones or otherwise, supply of product and similar arrangements.
5. Section 4.1 -Ownership
Section 4.1 is hereby deleted in its entirety and replaced with the following:
All Intellectual Property Rights in all aspects and parts of the Technology and Improvements shall be exclusively owned by the Owners, and/or Xxxxx Xxxxxxx and/or the UT as the case may be and nothing herein shall serve to, or should be construed to transfer any Intellectual Property Rights whatsoever in the Technology or Improvements except to the extent that any such Intellectual Property Rights are developed solely by the Licensee (with or without a third party) in which case the Licensee shall own or co-developed with the Licensee, in which case the Licensee shall have co-ownership rights in same as applicable.
6. Section 4.3 -Patents and Patent Applications.
Section 4.3 (a) is hereby deleted in its entirety and replaced with the following:
| (a) | Licensee, in the name of the Owners, and/or Xxxxx Xxxxxxx and/or UT (and as the case may be the Licensee if a joint developer) as the case may be, as assignee, shall file, prosecute and maintain the Patents. Licensee shall determine in which countries to pursue patent applications. In the event that Licensee elects not to continue prosecution in any country, UT may, at its sole discretion, file such patent or continue such prosecution in that country at its own expense. In such cases, any patents arising from such applications shall be excluded from the grant of rights under Section 2.1 herein for said country. |
Section 4.3 (e) is hereby deleted in its entirety and replaced with the following:
| (e) | Licensee undertakes to keep UT reasonably advised of the progress of prosecution and of any actions Licensee proposes to take or has taken in connection with the prosecution or maintenance of the Patents. Licensee shall provide UT with copies of correspondence and all actions issued by patent authorities and shall take into account any comments, remarks or suggestions UT may promptly provide to Licensee in writing at least ten (10) days prior to any due date established by Licensee for preparation of a response or amendment, and in all cases thirty (30) days prior to any patent office due date. |
7. Section 4.4 -Improvements
Section 4.4 is hereby amended by replacing the phrase at the third line, “the name of the Owners, or Xxxxx Xxxxxxx” with the name of the Owners and/or Xxxxx Xxxxxxx and/or UT (and, as the case may be) the Licensee if a joint developer)”
8. Section 7 -Notices.
Section 7.3 (a) is hereby deleted and replaced with the following:
| (a) | In the case of a notice to Licensee: |
Protagenic Therapeutics, Inc.
000 0xx Xxxxxx,
Xxxxx 000, Xxx Xxxx, XX 00000
U.S.A.
Attention: Xxxxxx Xxxxxxx, PhD, MSc
E-mail: xxxxxx.xxxxxxx@xx.xxx
With a copy to:
Gowlings Xxxxxxx Xxxxxxxxx XXX
0 Xxxxx Xxxxxxxx Xxxxx
000 Xxxx Xxxxxx Xxxx Xxxxx 0000
Xxxxxxx, Xxxxxxx X0X 0X0
Xxxxxx
Attention: Xxxxx Xxxxx
E-mail: xxxxx.xxxxx@xxxxxxxx.xxx
Section 7.3 (b) is hereby deleted and replaced with the following:
| (b) | In the case of a notice to UT: |
Innovations and Partnerships Office
Banting Institute, 000 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxx, Xxxxxxx X0X xX0
Xxxxxx
Attention: Xxxxxxxx Xxxxxx
Director, Innovations
E-mail: xxx.xxxxxx@xxxxxxxx.xx
| 9. | Schedule “A” is hereby amended by including the additional Improvements (Confidential Intellectual Property Disclosures & related Patents and Patent Applications) under the Schedule. |
| 10. | Schedule “B” is hereby amended by incorporating by reference the 2012 and the 2013 Sponsored Research Agreements to the Schedule and any other Research Agreement designated in same as being added by reference to Schedule B of the License Agreement between Licensee and The Governing Council of the University of Toronto. |
| 11. | Except as set out herein, this License Amendment shall not amend or modify any other provision within the License Agreement. |
| 12. | This License Amendment shall be governed by the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario |
IN WITNESS OF WHICH the Parties hereto have executed this First Amendment.
| PROTAGENIC THERAPEUTICS, INC. | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO | |||||
| By: | /s/ Xxxxxx Xxxxxxx |
By: | /s/ Xxxxxxxx Xxxxxx | |||
| Name: | Xxxxxx Xxxxxxx, PhD, MSc | Name | Xxxxxxxx Xxxxxx | |||
| Title: | Chief Operating Officer, President | Title: | Director, Innovations | |||
SCHEDULE A
Additional Improvements
Project Ref: P1323
Copies of listed Invention Disclosures Attached
| X.Xx. |
Confidential |
Date of |
Named |
Title of Disclosure |
Date of | |||||
| 1. | 10002701 | Jan 16, 2014 | Xxxxx Xxxx Xxxxxxx | Treatment of Insulin-Resistant Hyperglycemia by Teneurin C-Terminal Associated Peptide-1 | Feb 18, 2015 | |||||
| 2. | 10002574 | Mar 27, 2013 | Xxxxx Xxxx Xxxxxxx; Chand Dhan | Treatment of Human male Infertility by Use of Teneurin C-Terminal Associated Peptide (TCAP- 1) Administration | March 3, 2015 |
|
UNIVERSITY OF TORONTO | |
| CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE | ||
| Banting Institute, Room 413 | ||
| 000 Xxxxxxx Xxxxxx, Xxxxxxx, XX X0X 0X0 | ||
| Tel: (000) 000-0000 Fax: (000) 000-0000 email: xx.xxxxxxx@xxxxxxxx.xx |
1. Title of Invention: Treatment of insulin-resistant hyperglycemia by teneurin C-terminal associated peptide-1 administration
2. a) University of Toronto Inventors Individuals intimal to the University who have made an inventive contribution to this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary:
| SURNAME, GIVEN NAMES |
UNIVERSITY PERSONNEL NO. |
DEPARTMENT (List any cross |
AFFILIATION |
EMAIL ADDRESS |
CONTACT INFORMATION (mailing address phone, fax) | |||||
| Xxxxxxx Xxxxx Xxxx |
000000000 | Cell and Systems Biology |
Professor | David.xxxxxxx@ Xxxxxxxx.xx |
Tel: cell: 000 000 0000, home: 000 000 0000
Address: 000 Xxxxx Xxxxxx, Xxxxxxxxxxx, Xxxxxxx, X0X 0X0 |
b) External Inventors Non-University of Toronto Individuals who have made an inventive contribution to the Invention. i.e. sponsor employees, academic collaborators, etc. List name, organization and e-mail address.
not applicable
| For Research Services use only: Date Received: JAN 16 2014 |
DISCLOSURE REFERENCE NO: 10002701 |
Version: 2011.09.08
| c) | Contributors Individuals Internal or external to the University who have not made an Inventive Contribution to this Invention but have made a valuable contribution to the development of the Invention. List name organization and e-mail address. |
Protagenic Therapeutics Inc provided the majority of the funding for this project
Contact: Xx. Xxxxxx Xxxxxxx: xxxxxxxx@xxxxxxxxxx.xxx
3. Where did the work leading to this Invention take place? Please be specific
In vitro studies were conducted in rooms 304, 305 in Xxxxxx Xxxxxx Building at the University of Toronto. Animal studies were conducted in the Biosciences Support Facility central vivarium at Xxxxxx Xxxxxx. Hormone studies were performed under contract by Rules Based Medicine, a contract research organization (CRO)
4. Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate sheet if necessary.
TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and other tissues. It acts to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex leading to a signal transduction cascade to increase the number of glucose transporters in the cell membrane thereby increasing the transport of glucose into the cell. This action leads to significantly higher cellular energy in the form of increased cellular ATP levels. At the organismal level, single doses of TCAP-1 at 300 and 3000 pmoles significantly decrease blood glucose levels as long as one week later.
5. Have there been any prior disclosures (abstracts, presentations, publications) in respect of this Invention? List them and provide the date each disclosure occurred.
Chen C. Song X. xx Xxxxxx L, Xu M, Xxxxxxx R, Xxxxxxx DA (November. 2013) Insulin independent glucose transport and enhanced neuron metabolism by Teneurin C-terminal Associated Peptide (TCAP)-l Society for Neuroscience. San Diego, USA
| 6. | a) How was the work leading to this Invention funded? (I.e. salaries, equipment used, supplies |
etc.)
| SPONSOR |
PROJECT TITLE |
RIS FUND # | ||
| Protagenic Therapeutics Inc | Evidence for the existence of TCAP receptors | 495550 |
b) Was the project/work leading to this Invention subject to any software licence, material transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above?
x NO ¨ YES (please provide details)
| 7. | Have any patent applications or other intellectual property protection been filled in respect of this invention? |
¨ NO x YES (please provide details)
| 1. | AUSTRALIA: September 2010. Patent Number: (May 2, 2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: XXXXXXX, Xxxxx; CHEWPOY, X. Xxxxxxx; BARSYTE, Xxxxx; XXXXXXXXX, Xxxxx. |
| 2. | UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin c- terminal peptides (TCAP) and uses thereof XXXXXXX, Xxxxx; CHEWPOY, X. Xxxxxxx; BARSYTE, Xxxxx; XXXXXXXXX, Xxxxx. |
8. Warranty:
I/We the Inventors listed in Section 2(a), have read, understood and agree to all of the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an ownership claim in this Invention are identified in Section 2(a) and 2(b).
| /s/ Xxxxx X. Xxxxxxx | ||||||||
| Signature | Date: 01/14/2014 | Signature | ||||||
| Typed Name:
|
Xxxxx X. Xxxxxxx | Typed Name: | ||||||
| Signature | Date | Signature | Date | |||||
| Typed Name: | Typed Name: | |||||||
|
|
UNIVERSITY OF TORONTO | |
| CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE | ||
| Banting Institute, Room 413 | ||
| 000 Xxxxxxx Xxxxxx, Xxxxxxx, XX X0X 1 L5 | ||
| Tel: (000) 000-0000 Fax: (000) 000-0000 email: xx.xxxxxxx@xxxxxxxx.xx |
1. Title of Invention: Treatment of human male infertility by use of teneurin C-terminal associated peptide (TCAP)-1 administration
2. a) University of Toronto Inventors Individuals internal to the University who have made an inventive contribution to this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary:
| SURNAME, GIVEN |
UNIVERSITY PERSONNEL NO. |
DEPARTMENT (List any cross |
AFFILIATION |
EMAIL ADDRESS |
CONTACT INFORMATION (mailing address phone, fax) | |||||
| Xxxxxxx Xxxxx Xxxx |
000000000 | Cell and Systems Biology | Professor | Xxxxx.xxxxxxx@xxxxxxxx.xx | Tel: 000 000 0000 Dept of Cell of Systems Biology Xxxxxx Xxxxxx Xxxx. 00 Xxxxxxx Xxxxxx, University of Toronto | |||||
| Chand Dhan |
000000000 | Cell and Systems Biology |
Ph.D. Graduate | Dhan.chand @xxxx.xxxxxxxx.xx |
Tel: 000 000 0000 Dept. of Cell of Systems Biology Xxxxxx Xxxxxx Xxxx. 00 Xxxxxxx xxxxxx. University of Toronto | |||||
b) External Inventors Non-University of Toronto individuals who have made an inventive contribution to the Invention, i.e. sponsor employees, academic collaborators, etc. List name, organization and email address.
not applicable
c) Contributors Individuals internal or external to the University who have not made an inventive contribution to this Invention but have made a valuable contribution to the development of the Invention. List name, organization and e-mail address.
Protagenic Therapeutics Inc provided the majority of the funding for this project
Contact: Xx. Xxxxxx Xxxxxxx: xxxxxxxx@xxxxxxxxxx.xxx
| For Research Services use only: Date Received: Mar 27 2013 |
DISCLOSURE REFERENCE NO: 10002574 |
| 3. | Where did the work leading to this Invention take place? Please be specific. |
In vitro studies were conducted in rooms 304, 305 in Xxxxxx Xxxxxx Building at the University of Toronto. Animal studies were conducted in the Biosciences Support Facility central vivarium at Xxxxxx Xxxxxx. Hormone studies were performed under contract by Rules Based Medicine a contract research organization (CRO).
| 4. | Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate sheet if necessary. |
TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and other tissues. It acts to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex. In the male reproductive system the teneurin-dystroglycan complex is associated with regions of the testes and epididymis that play a role in spermatozoa formation, maturation and viability. In vivo studies indicate that synthetic TCAP-l modifies testicular and epididymal morphology increases testes size and increases testosterone production. These effects are consistent with increased activity of the reproductive system in mate mice. However because the peptide and hormone system is highly conserved in all mammals as well as vertebrates in general, these studies suggest that synthetic TCAP-l has potential to be used to treat some forms of male infertility in humans as well as other species.
| 5. | Have there been any prior disclosures (abstracts, presentations, publications) in respect of this invention? List them and provide the date each disclosure occurred. |
Chand D, Colacci M, Xxxxx K, Xxxxxxx DA. (2012). Gonadal characterization of the evolutionary conserved teneurin-dystroglycan system in mouse. 26th Conference of European Comparative Endocrinologists, Zurich, Switzerland (August 2012)
| 6. | a) How was the work reading to this Invention funded? (i.e. salaries, equipment used, supplies etc.) |
| SPONSOR |
PROJECT TITLE |
RIS FUND # | ||
| Protagenic Therapeutics Inc | Existence for the existence of TCAP Receptors in neurons |
457526 |
| b) | Was the project/work leading to this Invention subject to any software licence, material transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above ? |
x NO ¨ YES (please provide details)
| 7. | Have any patent applications or other Intellectual property protection been filed in respect of this invention? |
| ¨ NO x YES (please provide details) |
| 1. | AUSTRALIA: September 2010. Patent Number: (May 2,2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: XXXXXXX, Xxxxx; CHEWPOY, X. Xxxxxxx; BARSYTE, Xxxxx; XXXXXXXXX, Xxxxx |
| 2. | UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin C-terminal peptides (TCAP) and uses thereof. XXXXXXX, Xxxxx; CBEWPOY, X. Xxxxxxx; BARSYTE, Xxxxx; XXXXXXXXX, Xxxxx. |
| 8. | Warranty: |
I/We. the Inventors listed in Section 2(a) , have read, understood and agree to all of the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an ownership claim in this Invention are identified in Section 2(a) and 2(b)
| /s/ Xxxxx X. Xxxxxxx | /s/ Xxx X. Xxxxx | |||||||
| Signature | Date: 03/20/2013 | Signature | Date: 03/20/2013 | |||||
| Typed Name:
|
Xxxxx X. Xxxxxxx | Typed Name: | Dhan X. Xxxxx | |||||
| Signature | Date | Signature | Date | |||||
| Typed Name: | Typed Name: | |||||||
SCHEDULE A (Continued)
Status Listing of Patent Applications filed for the Improvements
| TENEURIN C- TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF |
| Inventors: XXXXXXX, Xxxxx; CHEWPOY, X. Xxxxxxx; BARSYTE, Xxxxx; XXXXXXXXX, Xxxxx |
| COUNTRY |
REFERENCE# | TYPE | FILED | SERIAL # | XXXXXX | XXXXXX # | XXXXXX | |||||||||
| XXXXXX XXXXXX |
X0000000XXX0 (090931-360625) |
OTH | 05/03/2002 | 60/377,231 | EXPIRED | |||||||||||
| UNITED STATES |
T8476262USP2 (090931-360627) |
OTH | 11/06/2002 | 60/424,016 | EXPIRED | |||||||||||
| WIPO | T8476262WO (090931-360635) |
CEQ | 05/02/2003 | PCT/ CA03/00622 |
ENTERED NATIONAL PHASE | |||||||||||
| AUSTRALIA | T8476262AU (090931-360631) |
DCA | 05/02/2003 | 2003221575 | 09/23/2011 | 2003221575 | ISSUED | |||||||||
| CANADA | T8476262CA (090931-360629) |
DCA | 05/02/2003 | 2,482,810 | 06/10/2014 | 2,482,810 | ALLOWED | |||||||||
| EUROPEAN PATENT |
T8476262EP (090931-360633) |
DCA | 05/02/2003 | 03717086.7 | 03/12/2014 | 1499635 | GRANTED | |||||||||
| COMMENTS: |
Validated in France, Germany and Great Britain Opposition period is over; no opposition(s) filed | |||||||||||||||
| JAPAN | T8476262JP (090931-360634) |
DCA | 05/02/2003 | 2004-501444 | ABANDONED | |||||||||||
| UNITED STATES |
T8476262US (090931-360630) |
DCA | 11/01/2004 | 10/510,959 | 01/03/2012 | 8,088,889 | ISSUED | |||||||||
| XXXXXX XXXXXX |
X0000000XXXXX (090931-438501) |
CON | 11/09/2011 | 13/292,849 | PENDING | |||||||||||
A METHOD FOR INHIBITING NEURAL CELL DEATH
Inventor: XXXXXXX, Xxxxx
| COUNTRY |
REFERENCE# |
TYPE |
FILED |
SERIAL # |
ISSUED |
PATENT # |
STATUS | |||||||
| UNITED STATES |
T8476261USP (090931-370851) |
NEW | 02/15/2006 | 60/773,309 | EXPIRED | |||||||||
| UNITED STATES |
T8476261US (090931-387536) |
Non- provisional |
02/15/2007 | 11/706,376 | ABANDONED | |||||||||
| COMMENTS: This application was abandoned in lieu of filing a Continuation Application | ||||||||||||||
| UNITED STATES |
T8476261USCON (090931-435930) |
CON | 08/03/2011 | 13/197,575 | ABANDONED | |||||||||
| COMMENTS: July 1, 2014 – INSTRUCTIONS TO ABANDON APPLICATION RECEIVED | ||||||||||||||
| COMMENTS: This application is a Continuation of US application No. 11/706,376 | ||||||||||||||
A METHOD FOR REGULATING NEURITE GROWTH
Inventor: XXXXXXX, Xxxxx
| COUNTRY |
REFERENCE# |
TYPE |
FILED |
SERIAL # |
ISSUED |
PATENT # |
STATUS | |||||||
| UNITED STATES |
T8476288USP (090931-372046) |
NEW | 03/21/2006 | 60/783,821 | EXPIRED | |||||||||
METHOD FOR MODULATING GLUCOSE TRANSPORT USING TENEURIN C-TERMINAL ASSOCIATE PEPTIDE (TCAP)
Inventor: XXXXXXX, Xxxxx; XXXX, Xxxx
| COUNTRY |
REFERENCE# |
TYPE | FILED | SERIAL # | ISSUED | PATENT # | STATUS | |||||||
| UNITED STATES |
T8476302USP | Provisional | 07/18/2014 | 62/026,346 | PENDING | |||||||||
TENEURIN C-TERMINAL ASSOCIATED PEPTIDE (TCAP) AS AN ANTAGONIST OF LATROTOXIN
Inventor: XXXXXXX, Xxxxx A; X’XXXXXX, Xxxxxx X.
| COUNTRY |
REFERENCE# |
TYPE | FILED | SERIAL # | ISSUED | PATENT # | STATUS | |||||||
| UNITED STATES |
T8476314USP | Provisional | NOT FILED | |||||||||||
SCHEDULE B
Additional Research Agreement (s)
Copies of listed Sponsored Research Agreements Incorporated by Reference
Principal Investigator: Xxxxx Xxxx Xxxxxxx
| X.Xx. |
Research Agreement |
Effective Date |
End Date |
Project Title |
Fund Number | |||||
| 1. | Sponsored Research Agreement |
Apr 1, 2012 | March 31, 2013 | Evidence for existence of TCAP receptors in neurons | 495550 | |||||
| 2. | Sponsored Research Agreement |
Apr 1, 2013 | Xxxxx 00, 0000 | Xxxxxxxx C-terminal Associated Peptide (TCAP)-mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism | 495550 | |||||
